DALLAS, March 17, 2010 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring ACADIA Pharmaceuticals Inc (Nasdaq:ACAD). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at: http://www.stockpreacher.com/n/ACAD
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/StockPreacher
ACADIA Pharmaceuticals Inc. (ACAD) is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders. The Company is developing a portfolio consisting of its four product candidates, including pimavanserin, which is in Phase III development for the treatment of Parkinson's disease psychosis. In addition, the Company has a product candidate in phase II for chronic pain and a product candidate in phase I for glaucoma, both in collaboration with Allergan Inc., and ACP-106 in IND-track development. The Company's product candidates include pimavanserin, AGN-XX/YY, AC-262271 and ACP-106. The Company maintains two wholly owned subsidiaries: ACADIA Pharmaceuticals AB based in Malmo, Sweden and ACADIA Pharmaceuticals A/S based in Denmark.
Message Board Search for ACAD: http://www.boardcentral.com/boards/ACAD
In the report, the analyst notes:
"ACAD reported a net loss of $8.7 million, or $0.23 per common share, for the fourth quarter of 2009 compared to a net loss of $14.0 million, or $0.38 per common share, for the fourth quarter of 2008. The net loss for the fourth quarter of 2009 included charges of $1.3 million in connection with ACAD's restructuring announced in October.
"Pimavanserin is a small molecule product candidate that the Company discovered and advanced to phase III development as a treatment for patients with Parkinson's disease psychosis (PDP). Pimavanserin can be taken orally and blocks the activity of the 5-HT2A receptor, a key serotonin receptor that plays an important role in the treatment of various psychiatric disorders."
To read the entire report visit: http://www.stockpreacher.com/n/ACAD
See what investors are saying about ACAD at penny stock forum
StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com
StockPreacher.com Disclosure
StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly-owned by BlueWave Advisors, LLC. StockPreacher.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.